• All resolutions voted in accordance with Board of Directors’ recommendations
  • Khalil Barrage, Managing Director of Invus’ public equity investments division, appointed as new member of the Board of Directors


Paris (France), June 16, 2022 – 7:30 am CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, announces that the Combined General Meeting held today adopted all resolutions presented, in accordance with the Board of Directors’ recommendations.

Additionally, the Company’s shareholders approved the appointment of Mr. Khalil Barrage as a new Board member for a term of 3 years. Mr. Barrage is a Managing Director at Invus, based in New York. He joined Invus in 2003 and established its Public Equity activity. Since its inception, Invus Public Equity has concentrated its investments in the emerging innovative biotech companies. Prior to joining Invus, he worked at The Olayan Group in New York and ran their US equity portfolio for 15 years. He holds a BA in Economics from the American University of Beirut. He is a member of the board of several biotechs including Celtaxsys and Protagenic Therapeutics in the US and Sensorion in France. Shareholders also approved the renewal of the term of office of Board member GammaX Corporate Advisory, represented by Mr. Jacques Mallet, for an additional 3-year term.

Onxeo’s Board of Directors, chaired by Mrs. Shefali Agarwal, thus has 8 members, including 5 independent members.

Dr. Shefali Agarwal, Chairwoman, President and Chief Executive Officer of Onxeo, commented: “On behalf of the entire Onxeo team, I would like to thank all our shareholders for their commitment and their support at this General Meeting. I am excited to welcome Mr. Khalil Barrage to our board. Mr. Barrage brings a great wealth of experience and allows us to strengthen our ties with our main shareholder, a global fund that is highly engaged in the field of biotechnology and is committed to support innovative companies like ours through the next stages of our growth.  I will also like to congratulate Jacques Mallet, whose term of office has been renewed and who, in recent months, has provided considerable contribution to the Board and the company”.

The voting results and the minutes of the Shareholders’ General Meeting will be available within the statutory deadline on the Company’s website, in the General Meetings section.